InflaRx (NasdaqGS:IFRX) Update / briefing May 08, 2026 08:30 AM ET Speaker2 Thank you, John. Ladies and gentlemen, good morning. Thanks for listening in. It's our pleasure to be sharing with you our recent, you know, prioritization here on the renal space, particularly in the ANCA-associated vasculitis. May I please ask to forward the first slides? Please take note of the important notice and disclaimers. We will be making forward-looking statements. We're a publicly listed company, so I appreciate your tak ...